Shuttle Pharmaceuticals

IN THE PRESS

Press Releases

Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

August 15, 2024

·

4 min read

Press Releases

Shuttle Pharma’s Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE

July 19, 2024

·

3 min read

BioCapital

Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

May 22, 2024

·

2 min read

Business

Shuttle Pharma Provides First Quarter 2024 Corporate Update

May 14, 2024

·

5 min read

BioCapital

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024

April 3, 2024

·

2 min read

BioCapital

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on March 6, 2024

March 5, 2024

·

2 min read

Deals

Shuttle Pharma Announces Its Intent to Pursue a Rights Offering

February 13, 2024

·

5 min read

Drug Development

Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

January 8, 2024

·

4 min read

BioCapital

Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

December 11, 2023

·

5 min read

BioCapital

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on December 7, 2023

November 30, 2023

·

2 min read

JOBS